The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells

By sjmartinez • December 14, 2023

Lewis MI, Shapiro S, Oudiz RJ, Nakamura M, Geft D, Matusov Y, Hage A, Tapson VF, Henry TD, Azizad P, Saggar R, Mirocha J, Karpov OA, Van Eyk JE, Marbán E. The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells. EBioMedicine. 2023 Dec 7:104900. doi: 10.1016/j.ebiom.2023.104900. Epub ahead of print. PMID: 38092579.

Tags: Cardiology/Epi, Harbor UCLA, Progenitor cell therapy, Publications, pulmonary arterial hypertension, Regenerative medicine, right ventricle, Short- and long-term safety

Related Posts

The Cardiovascular Care of the Pediatric Athlete

Dean PN, Brothers JA, Burns K, Edelson JB, Etheridge S, Phelan DM, Shafer K, Snyder C, Molossi S, Danielian A, Friedman EM, Hsu J, Husaini[...]

Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study

Freaney PM, Huang X, Petito LC, Grobman WA, Catov J, Hauspurg A, Bairey Merz CN, Bello N, Kim JK, Lane A, Haas DM, Levine LD,[...]

Prototyping and Manufacturing of Customized Over-Encapsulated Polypills for Heart Failure with Reduced Ejection Fraction in a Safety-Net Healthcare System

DeJong C, Durstenfeld MS, Davis J, Wang CS, Chen J, Kazi DS, Hickey MD, Grochowski J, Steward WT, Riley ED, Zier LS, Moreau N, Huffman[...]